Human Genome Sciences Hepatitis C Drug Passes Test (Reuters


Reuters - Human Genome Sciences Inc. on Thursday
said its experimental drug for hepatitis C met its primary goal
in a mid-stage trial of patients who had not previously been
treated for the liver-damaging virus.

Read more...